Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Kansas
With
Pfizer
A double blind randomized study of celecoxib 400 mg bid versus placebo in newly diagnosed breast cancer. Assessment of modulation of tissue markers (Ki-67, ER, VEGF, PR, etc.) and serum markers (estradiol, estrone, SHBG, etc.).
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
women with a recent diagnosis of T1 or T2 non-invasive breast cancer by large core needle or excisional biopsy
confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post-diagnostic analyses to perform research assessments
reexcision planned within 10 days to 6 weeks from study start
if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
You may not be if
no hormone replacement therapy within the 90 days prior to biopsy
if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
no evidence of metastatic malignancy of any kind
no history of asthma, allergy ASA, NSAIDS, celecoxib or other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study.
no celecoxib or rofecoxib use within one month of biopsy
no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
no current anticoagulants
no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study
no aromatase inhibitor in the six months prior to participation
no concomitant lithium
no known significant bleeding disorder
Clareo Health | A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
